EGFR and interstitial lung disease: On the other hand, in the ILD Set, these categories were as follows: PD-1 inhibitors (8 cases), programmed death-ligand 1 inhibitors (1 case), EGFR-TKIs (21 cases), ALK-TKIs (8 cases), vascular endothelial growth factor inhibitors (4 cases), and cytotoxic agents (34 cases).